

Amendment re 10/7/04 Official Action
Application No. 10/632,281

IN THE CLAIMS:

Please cancel claims 3, 5, and 11, without prejudice. Please amend claims 1-2, 6-10, and 12-15 in accordance with 37 C.F.R. § 1.121.

1. (Amended) A method of treating [cell proliferative diseases] cancer comprising administration in a therapeutic regimen of (an) a panerb B inhibitor [of at least one erb B tyrosine kinase] and at least one antineoplastic agent selected from the group consisting of gemcitabine, paclitaxel, docetaxel, cisplatin, carboplatin, etoposide, adriamycin, topotecan, CPT-11, capecitabine, [or] and pharmaceutically acceptable salts thereof, or ionizing radiation].
2. (Amended) The method of Claim 1 wherein said panerb B inhibitor [of the erbB tyrosine kinase] is an irreversible inhibitor.
3. (Canceled)
4. (Original) The method according to Claim 2 wherein said inhibitor is N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide.
5. (Canceled)
6. (Amended) The method according to Claim 1 wherein said at least one [said] antineoplastic agent is gemcitabine or a pharmaceutically acceptable salt thereof.
7. (Amended) The method according to Claim [6] 1 wherein said at least one [said] antineoplastic agent is a taxane or a pharmaceutically acceptable salt thereof.
8. (Amended) [A combination] The method according to Claim 1 wherein said at least one antineoplastic agent is selected from the group consisting of paclitaxel [or] and docetaxel.
9. (Amended) A method of treating [a hyperproliferative cellular disorder] cancer comprising administered to a mammal in need of treatment an amount of at least one panerb B [erbB] tyrosine kinase inhibitor and at least one antineoplastic agent according to Claim 1 in an amount sufficient to inhibit [cellular hyperproliferation] cancer cell growth.
10. (Amended) The method of Claim 9 wherein said cancer is selected from the group [comprising] consisting of solid tumors, non-small cell lung cancer, squamous cell carcinoma, glioma, small cell lung carcinoma, endometrial cancer, thyroid cancer,

Amendment re 10/7/04 Official Action
Application No. 10/832,281

melanoma, colorectal cancer, bladder cancer, renal cell cancer, pancreatic cancer, head and neck cancer such as esophageal [or] cancer, cervical cancers, ovarian cancer, myeloma, prostate cancer, sarcomas, chronic myelogenous leukemia, and breast cancer.

11. (Canceled)
12. (Amended) The method of Claim [1] comprising administering [CI-1033] said inhibitor in a therapeutic regimen with at least one antineoplastic agent selected from the group [comprising] consisting of gemcitabine, paclitaxel, taxotere, cisplatin, carboplatin, etoposide, adriamycin, topotecan, CPT-11, and capecitabine[, or ionizing radiation].
13. (Amended) The method according to Claim 2, wherein the antineoplastic agent is administered prior to the panerb B [erbB] tyrosine kinase inhibitor.
14. (Amended) The method according to Claim 2, wherein the antineoplastic agent is administered at the same approximate time as the panerb B tyrosine kinase inhibitor .
15. (Amended) The method according to Claim 2, wherein the antineoplastic agent is administered [following] after the panerb B tyrosine kinase inhibitor .